Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

Dr. Sznol Discusses the Combination of Ipilimumab and Nivolumab in Melanoma

Publication date: Sep 11, 2019

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab, in melanoma.

Website: https://www.onclive.com

Twitter: https://twitter.com/OncLive

Facebook: https://www.facebook.com/OncLive/

LinkedIn: https://www.linkedin.com/company/onclive

Concepts Keywords
Brain Breakthrough therapy
Embolism Antineoplastic drugs
Europe Monoclonal antibodies
Immunotherapy Ipilimumab
Inhibitor RTT
Ipilimumab Organ systems
Israel Clinical medicine
LinkedIn Bristol-Myers Squibb
Mab Medicine
Mario Nivolumab
Medicine Immunotherapy
Melanoma Melanoma
Mets Skin cancer
Novella
Randomized Trial
Tilly
Toxicity
Yale

Semantics

Type Source Name
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH Skin Cancer
disease DOID Skin Cancer
disease MESH Cancer
disease DOID Cancer
gene UNIPROT CTLA4
gene UNIPROT RPL17
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *